Valeant Pharma (VRX) Off Lows as Charges Relate to Employee Fraud Versus Company Fraud
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Valeant Pharma (NYSE: VRX) is bouncing off morning lows as the charges against former exec Gary Tanner and CEO the Philidor Andrew Davenport appear more related to individual fraud versus company fraud. Shares of VRX are down 2% after trading down 7% earlier.
From the complaint:
"The kickback payments were made in secret and were laundered though a series of shell companies and transactions designed to conceal the illicit source."
"Without Valeant's knowledge or approval, TANNER ultimately received close to $10 million in kickbacks from DAVENPORT...."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NCI, Inc. (NCIT) Controller Embezzled Money
- Stocks with Implied Volatility Movement
- Stocks with increasing call volume on January 20
Create E-mail Alert Related CategoriesLitigation, Short Sales, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!